32 C
Vientiane
Monday, October 20, 2025
spot_img
Home Blog Page 530

Meet the Roborock H60 Hub Ultra: Cordless Cleaning with Auto-Empty Ease

Roborock launches the H60 Hub Ultra cordless stick vacuum in Australia, delivering deep-cleaning performance with hands-free dust disposal for the ultimate everyday convenience.

SYDNEY, Aug. 28, 2025 /PRNewswire/ — Roborock, a global leader in ultra-intelligent home robotics, is raising the bar for cordless vacuuming in Australia with the launch of the H60 Hub Ultra. Blending powerful suction, long-lasting battery life, and Roborock’s latest self-emptying dock technology, the H60 Hub Ultra is built to take the effort out of deep cleaning – and keep homes effortlessly spotless with minimal maintenance.


“At Roborock, we believe that smart cleaning should be seamless and fit effortlessly into everyday life,” said Richard Chang, Founder & CEO of Roborock. “With the H60 Hub Ultra, we’re combining flagship-level power with the convenience of automatic dust disposal, so Australians can spend less time on chores and more time doing what they love. It’s about delivering a smarter, more hygienic clean without the usual hassle — a vacuum that truly works for you.”

Deep Cleaning Meets Cordless Convenience

The H60 Hub Ultra delivers a powerful 210AW of suction, enough to lift embedded dust and debris from deep within carpets and along hard floor edges. Backed by TÜV Rheinland certification, it offers robust, reliable cleaning with up to 90 minutes of runtime on a single charge, giving users the freedom to clean large areas without interruption. Its lightweight build and telescopic wand make it easy to manoeuvre, while the detachable battery provides flexible charging options and extended runtime when needed.

Smarter Storage with Auto-Empty Dock

Say goodbye to messy dustbins and hello to true convenience. The H60 Hub Ultra’s auto-empty dock takes care of dust disposal in just 10 seconds, transferring debris into a 3L sealed dust bag that holds up to 100 days’ worth of dirt. Once docked, the vacuum also recharges automatically, ready for the next clean. With an ergonomic docking height of 848mm and retractable wand design, docking is simple and comfortable — no awkward lifting required.

See the Dust, Clean with Confidence


Cleaning just got smarter with the H60’s 140° wide-angle green dust detection light, which illuminates hidden dirt and dust across a broad path so nothing gets missed. Whether you’re vacuuming under furniture or across high-traffic areas, this clever light helps ensure a more thorough, consistent clean every time.

Designed for a More Hygienic Home

The sealed dust bags on the H60 Hub Ultra are designed to trap 99% of bacteria, helping keep dust and allergens securely contained. Inside the vacuum, a 5-stage filtration system, including a HEPA filter, captures 99.95% of microdust particles as small as 0.3 microns, while a 9-cyclone separation system maintains strong, steady suction by preventing clogs. It’s everything you need for a cleaner home, and cleaner air.

Built to Tackle Every Mess


The H60 Hub Ultra comes with a complete range of versatile attachments to take on any surface or situation. The JawScrapers™ anti-tangle brush, which achieves a 0% tangle rate, features a curved shark-tooth design and fibre-rubber roller to actively prevent hair wrap — ideal for pet owners and long-haired households. A motorised mini-brush makes short work of upholstery and mattresses, while the 2-in-1 crevice tool is perfect for corners, baseboards, and other hard-to-reach spots. And with built-in dock storage, your tools stay organised and within reach.

Pricing and Availability

The Roborock H60 Hub Ultra will be available in Australia from 28 August 2025 at RRP $999 through Roborock’s Official Online Store and Participating Online Retailers.

For more information, visit: https://au.roborock.com

About Roborock
Roborock is a leading smart cleaning brand renowned for its intelligent cleaning solutions. With a steadfast dedication to becoming a global leader in smart appliances, Roborock enriches lives with its innovative line of robotic, cordless, wet/dry vacuum cleaners, and washer-dryers. Rooted in a user-centric approach, our R&D-driven solutions cater to diverse cleaning needs in over 15 million homes across 170+ countries. Headquartered in Beijing and with strategic subsidiaries worldwide, including the United States, Japan, Germany, and Australia, Roborock is committed to simplifying the way the world cleans.

 

AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

HONG KONG, Aug. 28, 2025 /PRNewswire/ — AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are being optimized. Four core innovative products are poised for commercialization, and significant advancements have been made in overseas market expansion. Two mRNA technology vaccines have simultaneously received clinical trial approvals in both the PRC and the U.S., leading to optimistic forecasts from institutions. A recent report[1] by DBS Bank predicts nearly 60% upside potential for the company’s stock price compared to current levels.

Confirmed Major Products Expected to Achieve Profitability by 2026

According to the interim report, AIM’s 13-valent pneumococcal conjugate vaccine has applied for market registration and completed on-site verification. The application for its serum-free rabies vaccine has been accepted, while the 23-valent pneumococcal polysaccharide vaccine has finished Phase III clinical serological tests and is set to enter the statistical unblinding phase. The iterative process for the high-efficiency diploid rabies vaccine is currently in Phase III clinical trials, expected to conclude by the end of 2025, with a market registration application planned for 2026.

DBS Bank’s research report forecasts that AIM Vaccine is likely to achieve profitability by 2026. By then, AIM is projected to become the leading manufacturer of rabies and pneumococcal vaccines in the PRC, capturing approximately 20% and 10% market shares, respectively. Sales from 2025 to 2027 are anticipated to grow at a compound annual growth rate of 45%.

mRNA Technology Platform Gains International Recognition, Leading R&D Innovation in the Industry

As highlighted in the interim report, AIM Vaccine continues to excel in R&D, currently possessing 20 vaccine products in development targeting 12 diseases, with 23 clinical approvals and 24 clinical trials underway. Among these, seven are Category I innovative vaccines, with three having received approval to commence clinical trials. Notably, the mRNA shingles vaccine and mRNA respiratory syncytial virus vaccine have both obtained clinical approval in the U.S. and PRC, marking international validation of the company’s mRNA technology platform.

AIM has also laid plans for mRNA rabies and influenza vaccines, which hold significant market potential. The mRNA rabies vaccine is characterized by a notable reduction in vaccination doses, higher protective neutralizing antibodies, faster production speeds, and strong immune persistence.

Given the platform’s advancement and maturity, AIM’s mRNA technology has been validated through thousands of clinical trial subjects, confirming its safety and efficacy and laying a solid foundation for future mRNA vaccine developments.

Moreover, amid the trend of innovative drug exports, AIM Vaccine has showcased its strengths. In the first half of the year, the company’s quadrivalent meningococcal polysaccharide vaccine successfully entered the African market, the rabies vaccine debuted in Central America, the hepatitis B vaccine is actively progressing through registration processes in Southeast Asia, and the hepatitis A vaccine is advancing registration in South Asia. The registration work for the quadrivalent meningococcal polysaccharide vaccine in Central Asia is also steadily progressing, with local market entry expected next year.

Meanwhile, AIM is actively preparing for the internationalization of the 13-valent pneumococcal conjugate vaccine and the serum-free rabies vaccine, having secured exclusive agency agreements with multiple countries in West and Southeast Asia. A formal memorandum of understanding for the 13-valent pneumococcal conjugate vaccine has been signed with Egypt, further expanding its market presence in the Middle East and North Africa.

With strong technological innovation represented by mRNA, several major products nearing commercialization, and broad overseas market strategies, AIM Vaccine has garnered optimistic expectations from institutions. The DBS report predicts that performance turning points will drive a reassessment of AIM Vaccine’s stock price, estimating a fair value of HKD 8.3 per share, indicating nearly 60% upside potential compared to current levels.

Currently, the enthusiasm for innovative drugs in the capital market remains strong. Multiple investment institutions believe that with favorable industry policies and capital enthusiasm, companies with genuine innovative capabilities are expected to experience significant market value growth. As an industry leader, AIM Vaccine is well-positioned to navigate an optimistic market amid the convergence of performance and valuation.

 

Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study

–          ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison.

–          Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron.

–         Topline data from the Ascletis’ U.S. Phase IIa study for ASC30 in participants with obesity or overweight are expected in the fourth quarter of 2025.

HONG KONG, Aug. 28, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces promising topline pharmacokinetic (PK) data from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2). At steady state, ASC30 demonstrated drug exposures (area under the curve over 0-24 hours or AUC0-24h) of 3,560 ng•h/mL and 5,060 ng•h/mL for cohort 1 (20 mg) and cohort 2 (40 mg) , respectively, in the Phase Ib MAD study. These drug exposure data are consistent with placebo-adjusted mean body weight reduction from baseline of 4.5% for cohort 1 (20 mg) and 6.5% for cohort 2 (40 mg) after 28-day treatment, indicating higher drug exposures are associated with greater weight loss.

Based on a cross-trial comparison, 20 mg and 40 mg ASC30 oral once-daily tablet demonstrated greater drug exposure of approximately 2.3-fold and 3.3-fold, respectively, of orforglipron oral once-daily capsule (24 mg cohort, AUC0-24h 1,520 ng•h/mL) [1]. After 28-day treatment, orforglipron (24 mg cohort, AUC0-24h 1,520 ng•h/mL) resulted in only 3.6% placebo-adjusted mean body weight reduction from baseline [1]. Despite high drug exposure of ASC30 in cohort 1 (20 mg, AUC0-24h 3,560 ng•h/mL), there were no incidences of vomiting in cohort 1 (20 mg), whereas orforglipron 24 mg cohort (AUC0-24h 1,520 ng•h/mL) had 18% vomiting[1], suggesting the Ascletis’ chemical lead and formulation optimization strategies played a role in tolerability improvement.

In the Phase Ib MAD study, ASC30 oral once-daily tablet was safe and well tolerated with no serious adverse events (SAEs) reported and no Grade 3 or higher adverse events (AEs) including GI-related AEs observed. There were no elevations of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBL) during the treatment. There were no abnormal findings in laboratory tests, vital signs, ECGs (electrocardiograms, including QTc intervals), and physical exams.

“Based on recent clinical data published to date, we believe higher drug exposure leads to greater weight loss for small molecule GLP-1 receptor (GLP-1R) agonists including orforglipron,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “I am pleased to see that the higher drug exposures of ASC30 seen in a head-to-head study in non-human primates with orforglipron translated to humans at approximately 2.3-fold to 3.3-fold greater than orforglipron in a cross-trial comparison. Given that higher drug exposures of ASC30 produced more weight loss in participants with obesity, we believe that ASC30 oral once-daily tablet may potentially be competitive and differentiated for the treatment of obesity compared to orforglipron.”

Ascletis announced in early August 2025 that it completed enrollment in its U.S. Phase IIa study for ASC30 in 125 participants with obesity or overweight, with topline data expected in the fourth quarter of 2025.

[1] Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634‐2641. doi:10.1111/ dom.15184.

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions. 

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist in development as a once-daily oral tablet and once-monthly subcutaneous injection for weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

To learn more about Ascletis, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

SK hynix Starts Supplying Mobile DRAM with Highly Efficient Heat Dissipation

  • Company first in industry to develop High-K EMC material, improves thermal conductivity by 3.5 times, thermal resistance by 47%
  • Customers expect achievement to help address heat issue generated from on-device AI
  • SK hynix to lead next-generation DRAM for mobile device through technological innovation of materials

SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ — SK hynix Inc. (or “the company”, www.skhynix.com) announced today that it has started supplying mobile DRAM products with highly efficient heat dissipation by adopting the High-K Epoxy Molding Compound* material for the first time in the industry.

* EMC(Epoxy Molding Compound): a critical material for semiconductor packaging that protects chips from various external conditions such as water, heat, impact and electronic charge and provides a channel where heat can be dissipated. High-K EMC raises thermal conductivity with adoption of a material with high heat-transfer coefficient in EMC

The development comes as heat generated in the process of fast data transfer for on-device AI applications results in performance degradation of smartphones. Global smartphone companies welcome the launch of the product on expectations that it will help address the heat issue of high-performance flagship smartphones.

The structure of package on package, or PoP**, that most flagship smartphones adopt and stacks DRAM onto the application processor***, allows efficient use of limited space, while improving data transfer speed. Such system, however, also triggers a performance degradation of the device itself as heat generated within the mobile AP stays inside DRAM.

** PoP(Package on Package): a packaging method commonly used for mobile products. Different types of chips are stacked vertically to improve space efficiency, performance and flexibility of combinations

*** Mobile AP(Application Processor): chip referred to the brain of mobile devices such as smartphones and tablets

SK hynix found the solution in improvement of thermal conductivity of EMC, a critical material that covers DRAM package and developed High-K EMC by adding Alumina to Silica, which has been adopted for EMC material so far.

With thermal conductivity improved by 3.5 times and thermal resistance in the vertical course of the heat improved by 47%, the new technology is expected to contribute to a longer battery runtime and  product lifespan by improving performance of a smartphone and reducing power consumption.

“It’s a meaningful achievement that goes beyond a simple performance improvement as it addresses the inconvenience that many high-performance smartphone users may have had,” Lee Gyujei, Head of Package Product Development, said. “We are committed to firmly establishing our technological leadership in the next-generation mobile DRAM market with our technological innovation in materials.”

About SK hynix Inc.

SK hynix Inc., headquartered in Korea, is the world’s top tier semiconductor supplier offering Dynamic Random Access Memory chips (“DRAM”) and flash memory chips (“NAND flash”) for a wide range of distinguished customers globally. The Company’s shares are traded on the Korea Exchange, and the Global Depository shares are listed on the Luxembourg Stock Exchange. Further information about SK hynix is available at www.skhynix.com, news.skhynix.com.

Henan Launches Global Digital Tourism Platform at Expo 2025 Osaka to Grow Inbound Visitation

TOKYO, Aug. 27, 2025 /PRNewswire/ — On August 21, 2025, the Culture and Tourism Department of Henan Province introduced its new global digital tourism platform—“Journey of Civilization Light”—in Japan during Expo 2025 Osaka. The launch represents a major step forward in strengthening international cultural and tourism exchange.


During Henan Week at the Expo, more than one thousand promotional brochures and themed giveaways were shared through interactive activities, sparking interest among attendees. Journey of Civilization Light is a digital showcase designed to highlight Henan’s rich cultural legacy, historic landmarks, and scenic landscapes through immersive digital experiences. The platform provides global audiences with an accessible gateway to explore Henan’s attractions in greater depth. At the same time, in-person promotions were carried out in Tokyo in collaboration with leading travel agencies, while the online campaign drew more than ten thousand views. Together, these efforts connected directly with prospective visitors and generated strong demand for Henan’s tourism experiences in the Japanese market.

By building strategic partnerships with travel agencies in Osaka, Tokyo, and other key cities throughout Japan, and by sharing destination information widely, the initiative successfully reached its target audience. With the high profile of Expo 2025 and strong attention from international media, the campaign raised global awareness of the Laojia Henan brand and reinforced the cultural identity of “Henan, Where China Began.” Together, these efforts set the stage for continued growth in inbound travel to Henan.

Henan Tourism Promotion in South Korea Successfully Concludes

Creating a New Bridge for Cultural Exchange Between China and South Korea

SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ — From August 18 to 22, 2025, the Henan Provincial Department of Culture and Tourism presented its “Light of Culture” online exhibition and promotional showcase in Seoul, drawing strong participation from South Korean audiences. Visitors explored the rich cultural assets of Henan Province, gaining a deeper appreciation for the welcoming spirit of international cultural exchange.

The promotion featured both digital engagement and in-person activations. In partnership with CHINALAB, a leading South Korean online platform, the Henan Provincial Department of Culture and Tourism launched an interactive online exhibition that drew more than one million visits and generated strong feedback. The initiative significantly expanded awareness of Henan’s cultural offerings among South Korean audiences.


Complementing the digital campaign, the in-person program was staged in Seoul’s vibrant Hongdae district. Local cafés, including FLO-LOUNGE Flowercafe, showcased scenes and traditions from Central China, inviting guests to enjoy coffee in an atmosphere that reflected Henan’s cultural heritage. A branded coffee truck became a popular destination, offering more than a thousand complimentary beverages and promotional items, while creating an interactive setting where visitors could enjoy coffee while discovering all that Henan has to offer. The event provided an innovative way to connect Henan’s heritage with everyday life in Seoul.

The initiative successfully created a new platform for cultural exchange between China and South Korea, giving audiences in South Korea an authentic introduction to Henan’s cultural landscape while strengthening connections for future collaboration.

The event received coverage from major South Korean outlets, including The Korea JoongAng Daily and the travel magazine GUIDE ME.

 

 

 

Trip.com Group Limited Reports Unaudited Second Quarter and First Half of 2025 Financial Results

SINGAPORE, Aug. 28, 2025 /PRNewswire/ — Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) (“Trip.com Group” or the “Company”), a leading global one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours, and corporate travel management, today announced its unaudited financial results for the second quarter and first half of 2025.

Key Highlights for the Second Quarter of 2025

  •  International businesses sustained strong growth across all segments during the second quarter of 2025
    – Overall reservations on the Company’s international OTA platform increased by over 60% year-over-year.
    – Inbound travel bookings surged by over 100% year-over-year.
    – Outbound hotel and air ticket bookings have surpassed 120% of the pre-COVID level for the same period in 2019.

“Travel is a key driver in national growth and global engagement. It serves not only as an engine for economic development but also as a catalyst for cultural exchange, global understanding and social vitality,” said James Liang, Executive Chairman. “Looking ahead, we remain confident in the industry’s long-term growth, and will continue to prioritize strategic investments in innovation, partnership development , and inbound travel expansion to stimulate global economic advancement.”

“We are encouraged by the strong momentum across all segments of the travel industry,” said Jane Sun, Chief Executive Officer. “Our strategy focuses on capturing growing demand from every demographic, with special attention to inbound travel. At the same time, we are enhancing our service capabilities to provide global travelers with seamless local experiences. These efforts further reinforce our position as a trusted platform in the global travel landscape.”

Second Quarter of 2025 Financial Results and Business Updates

For the second quarter of 2025, Trip.com Group reported net revenue of RMB14.8 billion (US$2.1 billion), representing a 16% increase from the same period in 2024 and a 7% increase from the previous quarter, primarily driven by stronger travel demand, particularly during the holiday periods.

Accommodation reservation revenue for the second quarter of 2025 was RMB6.2 billion (US$869 million), representing a 21% increase from the same period in 2024, primarily driven by an increase in accommodation reservations. Accommodation reservation revenue for the second quarter of 2025 increased by 12% from the previous quarter, primarily driven by stronger travel demand, particularly during the holiday periods.

Transportation ticketing revenue for the second quarter of 2025 was RMB5.4 billion (US$753 million), representing an 11% increase from the same period in 2024, primarily driven by an increase in transportation reservations. Transportation ticketing revenue for the second quarter of 2025 was flat, compared to that of the previous quarter.

Packaged-tour revenue for the second quarter of 2025 was RMB1.1 billion (US$151 million), representing a 5% increase from the same period in 2024, primarily driven by an increase in packaged-tour reservations. Packaged-tour revenue for the second quarter of 2025 increased by 14% from the previous quarter, primarily driven by stronger travel demand, particularly during the holiday periods.

Corporate travel revenue for the second quarter of 2025 was RMB692 million (US$97 million), representing a 9% increase from the same period in 2024 and a 21% increase from the previous quarter, primarily driven by an increase in corporate travel reservations.

Cost of revenue for the second quarter of 2025 increased by 22% to RMB2.8 billion (US$393 million) from the same period in 2024 and increased by 4% from the previous quarter, which was generally in line with the fluctuations in net revenue from the respective periods. Cost of revenue as a percentage of net revenue was 19% for the second quarter of 2025.

Product development expenses for the second quarter of 2025 increased by 17% to RMB3.5 billion (US$489 million) from the same period in 2024 primarily due to the increase in product development personnel related expenses. Product development expenses for the second quarter of 2025 decreased by 1% from the previous quarter. Product development expenses as a percentage of net revenue were 24% for the second quarter of 2025.

Sales and marketing expenses for the second quarter of 2025 increased by 17% to RMB3.3 billion (US$464 million) from the same period in 2024 and increased by 11% from the previous quarter, primarily due to the increase in expenses relating to sales and marketing promotion activities. Sales and marketing expenses as a percentage of net revenue were 22% for the second quarter of 2025.

General and administrative expenses for the second quarter of 2025 increased by 2% to RMB1.1 billion (US$153 million) from the same period in 2024 and increased by 6% from the previous quarter. General and administrative expenses as a percentage of net revenue were 7% for the second quarter of 2025.

Income tax expense for the second quarter of 2025 was RMB998 million (US$139 million), compared to RMB693 million for the same period in 2024 and RMB638 million for the previous quarter. The change in Trip.com Group’s effective tax rate was primarily due to the combined impacts of changes in respective profitability of its subsidiaries with different tax rates, changes in deferred tax liabilities relating to withholding tax, certain non-taxable income or loss resulting from the fair value changes in equity securities investments and exchangeable senior notes recorded in other income/(expense), and changes in valuation allowance provided for deferred tax assets.

Net income for the second quarter of 2025 was RMB4.9 billion (US$681 million), compared to RMB3.9 billion for the same period in 2024 and RMB4.3 billion for the previous quarter. Adjusted EBITDA for the second quarter of 2025 was RMB4.9 billion (US$680 million), compared to RMB4.4 billion for the same period in 2024 and RMB4.2 billion for the previous quarter.

Net income attributable to Trip.com Group’s shareholders for the second quarter of 2025 was RMB4.8 billion (US$676 million), compared to RMB3.8 billion for the same period in 2024 and RMB4.3 billion for the previous quarter. Excluding share-based compensation charges, fair value changes of equity securities investments and exchangeable senior notes recorded in other income/(expense), and their tax effects, non-GAAP net income attributable to Trip.com Group’s shareholders for the second quarter of 2025 was RMB5.0 billion (US$699 million), compared to RMB5.0 billion for the same period in 2024 and RMB4.2 billion for the previous quarter.

Diluted earnings per ordinary share and per ADS was RMB6.97 (US$0.97) for the second quarter of 2025. Excluding share-based compensation charges, fair value changes of equity securities investments and exchangeable senior notes recorded in other income/(expense), and their tax effects, non-GAAP diluted earnings per ordinary share and per ADS was RMB7.20 (US$1.01) for the second quarter of 2025. Each ADS currently represents one ordinary share of the Company.

As of June 30, 2025, the balance of cash and cash equivalents, restricted cash, short-term investment, and held to maturity time deposit and financial products was RMB94.1 billion (US$13.1 billion).

Recent Development

As part of the Company’s ongoing commitment to delivering value to its shareholders and ADS holders and in line with its regular capital return policy, as of August 27, 2025, U.S. Eastern Time, the Company had repurchased 7 million ADSs in aggregate with a total gross consideration of US$400 million pursuant to its existing share repurchase program authorized in February 2025.

In August 2025, the board of directors of the Company (the “Board”) has authorized a new share repurchase program under which the Company may repurchase up to an aggregate of US$5 billion of its outstanding ordinary shares and/or ADSs. The share repurchases may be made from time to time in the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations as well as repurchase mandate granted or to be granted to the Board pursuant to the resolutions of shareholders passed at the annual general meeting of the Company (to the extent applicable).

Conference Call

Trip.com Group’s management team will host a conference call at 8:00 PM on August 27, 2025, U.S. Eastern Time (or 8:00 AM on August 28, 2025, Hong Kong Time) following this announcement.

The conference call will be available live on Webcast and for replay at: https://investors.trip.com. The call will be archived for twelve months on our website.

All participants must pre-register to join this conference call using the Participant Registration link below:

https://register-conf.media-server.com/register/BI721587a0c39340f2abf725eb0ffb89eb

Upon registration, each participant will receive details for this conference call, including dial-in numbers and a unique access PIN. To join the conference, please dial the number provided, enter your PIN, and you will join the conference instantly.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” “is/are likely to,” “confident,” or other similar statements. Among other things, quotations from management in this press release, as well as Trip.com Group’s strategic and operational plans, contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, severe or prolonged downturn in the global or Chinese economy, general declines or disruptions in the travel industry, volatility in the trading price of Trip.com Group’s ADSs or shares, Trip.com Group’s reliance on its relationships and contractual arrangements with travel suppliers and strategic alliances, failure to compete against new and existing competitors, failure to successfully manage current growth and potential future growth, risks associated with any strategic investments or acquisitions, seasonality in the travel industry in the relevant jurisdictions where Trip.com Group operates, failure to successfully develop Trip.com Group’s existing or future business lines, damage to or failure of Trip.com Group’s infrastructure and technology, loss of services of Trip.com Group’s key executives, adverse changes in economic and business conditions in the relevant jurisdictions where Trip.com Group operates, any regulatory developments in laws, regulations, rules, policies or guidelines applicable to Trip.com Group and other risks outlined in Trip.com Group’s filings with the U.S. Securities and Exchange Commission or the Stock Exchange of Hong Kong Limited. All information provided in this press release and in the attachments is as of the date of the issuance, and Trip.com Group does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Non-GAAP Financial Measures

To supplement Trip.com Group’s consolidated financial statements, which are prepared and presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Trip.com Group uses non-GAAP financial information related to adjusted net income attributable to Trip.com Group Limited, adjusted EBITDA, adjusted EBITDA margin, and adjusted diluted earnings per ordinary share and per ADS, each of which is adjusted from the most comparable GAAP result to exclude the share-based compensation charges that are not tax deductible, fair value changes of equity securities investments and exchangeable senior notes recorded in other income/(expense), net of tax, and other applicable items. Trip.com Group’s management believes the non-GAAP financial measures facilitate better understanding of operating results from quarter to quarter and provide management with a better capability to plan and forecast future periods.

Non-GAAP information is not prepared in accordance with GAAP, does not have a standardized meaning under GAAP, and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using non-GAAP financial measures is that non-GAAP measures exclude share-based compensation charges, fair value changes of equity securities investments and exchangeable senior notes recorded in other income/(expense), and their tax effects that have been and will continue to be significant recurring expenses in Trip.com Group’s business for the foreseeable future.

Reconciliations of Trip.com Group’s non-GAAP financial data to the most comparable GAAP data included in the consolidated statement of operations are included at the end of this press release.

About Trip.com Group Limited

Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) is a leading global one-stop travel platform, integrating a comprehensive suite of travel products and services and differentiated travel content. It is the go-to destination for many travelers in Asia, and increasingly for travelers around the world, to explore travel, get inspired, make informed and cost-effective travel bookings, enjoy hassle-free on-the-go support, and share travel experience. Founded in 1999 and listed on Nasdaq in 2003 and HKEX in 2021, the Company currently operates under a portfolio of brands, including Ctrip, Qunar, Trip.com, and Skyscanner, with the mission “to pursue the perfect trip for a better world.”

For further information, please contact:

Investor Relations
Trip.com Group Limited
Tel: +86 (21) 3406-4880 X 12229
Email: iremail@trip.com

 

Trip.com Group Limited

Unaudited Consolidated Balance Sheets

(In millions, except share and per share data)

December 31, 2024

June 30, 2025

June 30, 2025

RMB (million)

RMB (million)

USD (million)

ASSETS

Current assets:

Cash, cash equivalents and restricted cash

51,093

58,313

8,140

Short-term investments

28,475

21,705

3,030

Accounts receivable, net 

12,459

14,413

2,012

Prepayments and other current assets 

20,093

22,085

3,083

Total current assets

112,120

116,516

16,265

Property, equipment and software

5,053

5,394

753

Intangible assets and land use rights

12,840

12,967

1,810

Right-of-use asset

755

766

107

Investments (Includes held to maturity time deposit and
financial products of RMB10,453 million and RMB14,097
million as of December 31,2024 and June 30, 2025,
respectively)

47,194

51,121

7,136

Goodwill

60,911

61,884

8,639

Other long-term assets

454

514

72

Deferred tax asset

3,254

3,276

457

Total assets

242,581

252,438

35,239

LIABILITIES

Current liabilities:

Short-term debt and current portion of long-term debt

19,433

28,202

3,937

Accounts payable

16,578

19,506

2,723

Advances from customers

18,029

19,692

2,749

Other current liabilities

19,970

20,054

2,800

Total current liabilities

74,010

87,454

12,209

Deferred tax liability

4,098

3,640

508

Long-term debt

20,134

10,938

1,527

Long-term lease liability

561

543

76

Other long-term liabilities

296

383

53

Total liabilities

99,099

102,958

14,373

MEZZANINE EQUITY

743

791

110

SHAREHOLDERS’ EQUITY

Total Trip.com Group Limited shareholders’ equity

141,807

147,646

20,610

Non-controlling interests

932

1,043

146

Total shareholders’ equity

142,739

148,689

20,756

Total liabilities, mezzanine equity and shareholders’
equity

242,581

252,438

35,239

 

Trip.com Group Limited

Unaudited Consolidated Statements of Income

(In millions, except share and per share data)

Three Months Ended

Six Months Ended

June 30, 2024

March 31, 2025

June 30, 2025

June 30, 2025

June 30, 2024

June 30, 2025

June 30, 2025

RMB (million)

RMB (million)

RMB (million)

USD (million)

RMB (million)

RMB (million)

USD (million)

Revenue:

Accommodation reservation 

5,136

5,541

6,225

869

9,632

11,766

1,642

Transportation ticketing 

4,871

5,418

5,397

753

9,871

10,815

1,510

Packaged-tour 

1,025

947

1,079

151

1,908

2,026

283

Corporate travel

633

573

692

97

1,144

1,265

177

Others

1,123

1,371

1,471

205

2,154

2,842

397

Total revenue

12,788

13,850

14,864

2,075

24,709

28,714

4,009

Less: Sales tax and surcharges

(16)

(20)

(21)

(3)

(32)

(41)

(6)

Net revenue

12,772

13,830

14,843

2,072

24,677

28,673

4,003

Cost of revenue

(2,312)

(2,705)

(2,818)

(393)

(4,550)

(5,523)

(771)

Gross profit

10,460

11,125

12,025

1,679

20,127

23,150

3,232

Operating expenses:

Product development *

(2,993)

(3,525)

(3,500)

(489)

(6,102)

(7,025)

(981)

Sales and marketing *

(2,835)

(2,999)

(3,326)

(464)

(5,147)

(6,325)

(883)

General and administrative *

(1,077)

(1,038)

(1,097)

(153)

(2,008)

(2,135)

(298)

Total operating expenses

(6,905)

(7,562)

(7,923)

(1,106)

(13,257)

(15,485)

(2,162)

Income from operations

3,555

3,563

4,102

573

6,870

7,665

1,070

Interest income 

634

640

609

85

1,226

1,249

174

Interest expense

(514)

(286)

(265)

(37)

(1,013)

(551)

(77)

Other (expense)/income

(183)

1,137

1,114

155

576

2,251

314

Income before income tax

expense and equity in

income/(loss) of affiliates

3,492

5,054

5,560

776

7,659

10,614

1,481

Income tax expense

(693)

(638)

(998)

(139)

(1,357)

(1,636)

(228)

Equity in income/(loss) of affiliates

1,089

(102)

318

44

1,911

216

30

Net income

3,888

4,314

4,880

681

8,213

9,194

1,283

Net income attributable to non-
controlling interests and mezzanine
classified non-controlling interests

(55)

(37)

(34)

(5)

(68)

(71)

(10)

Net income attributable to

Trip.com Group Limited

3,833

4,277

4,846

676

8,145

9,123

1,273

Earnings per ordinary share 

– Basic

5.84

6.48

7.34

1.02

12.46

13.82

1.93

– Diluted

5.57

6.09

6.97

0.97

11.93

13.05

1.82

Earnings per ADS 

– Basic

5.84

6.48

7.34

1.02

12.46

13.82

1.93

– Diluted

5.57

6.09

6.97

0.97

11.93

13.05

1.82

Weighted average ordinary shares
outstanding 

– Basic

655,857,569

660,203,576

659,916,799

659,916,799

653,603,638

660,060,247

660,060,247

– Diluted

687,977,626

702,144,923

695,705,348

695,705,348

682,766,701

698,925,198

698,925,198

* Share-based compensation included in Operating expenses above is as follows:

  Product development 

322

220

258

36

536

478

67

  Sales and marketing 

55

41

53

7

93

94

13

  General and administrative 

297

219

255

35

495

474

66

 

Trip.com Group Limited

Unaudited Reconciliation of  GAAP and Non-GAAP Results

(In millions, except %, share and per share data)

Three Months Ended

Six Months Ended

June 30, 2024

March 31, 2025

June 30, 2025

June 30, 2025

June 30, 2024

June 30, 2025

June 30, 2025

RMB (million)

RMB (million)

RMB (million)

USD (million)

RMB (million)

RMB (million)

USD (million)

Net income

3,888

4,314

4,880

681

8,213

9,194

1,283

Less: Interest income

(634)

(640)

(609)

(85)

(1,226)

(1,249)

(174)

Add: Interest expense

514

286

265

37

1,013

551

77

Add: Other expense/(income)

183

(1,137)

(1,114)

(155)

(576)

(2,251)

(314)

Add: Income tax expense

693

638

998

139

1,357

1,636

228

Less: Equity in (income)/loss of affiliates

(1,089)

102

(318)

(44)

(1,911)

(216)

(30)

Income from operations

3,555

3,563

4,102

573

6,870

7,665

1,070

Add: Share-based compensation

674

480

566

78

1,124

1,046

146

Add: Depreciation and amortization

207

204

212

29

416

416

58

Adjusted EBITDA

4,436

4,247

4,880

680

8,410

9,127

1,274

Adjusted EBITDA margin

35 %

31 %

33 %

33 %

34 %

32 %

32 %

Net income attributable to Trip.com Group Limited

3,833

4,277

4,846

676

8,145

9,123

1,273

Add: Share-based compensation

674

480

566

78

1,124

1,046

146

Add: Loss/(gain) from fair value changes of equity securities
investments and exchangeable senior notes

435

(526)

(447)

(62)

(244)

(973)

(136)

Add: Tax effects on fair value changes of equity securities

investments and exchangeable senior notes

43

(43)

46

7

15

3

0

Non-GAAP net income attributable to Trip.com Group Limited

4,985

4,188

5,011

699

9,040

9,199

1,283

Weighted average ordinary shares outstanding-
 Diluted-non GAAP 

687,977,626

702,144,923

695,705,348

695,705,348

682,766,701

698,925,198

698,925,198

Non-GAAP Diluted income per share 

7.25

5.96

7.20

1.01

13.24

13.16

1.84

Non-GAAP Diluted income per ADS 

7.25

5.96

7.20

1.01

13.24

13.16

1.84

Notes for all the condensed consolidated financial schedules presented:

Note 1: The conversion of Renminbi (RMB) into U.S. dollars (USD) is based on the certified exchange rate of USD1.00=RMB7.1636 on June 30, 2025 published by the Federal Reserve Board.

Manny Halley Greenlights “True to the Game” TV Series

Series is Based on New York Times Best Selling Novel and Expands the Popular “True the Game” Franchise Beyond the Feature Film Trilogy

LOS ANGELES, Aug. 28, 2025 /PRNewswire/ — Manny Halley (True to the Game, Dutch, SoulMates) is expanding the popular True to the Game franchise, making a new TV series adapted from Terri Woods’ New York Times best-selling book series, that will star Sierra Capri (On My Block), Bentley Green (White Men Can’t Jump), Vivica A. Fox (Independence Day), Angell Conwell (The Young and the Restless) and Carl Anthony Payne II (Martin, Young Dylan).

True to the Game brings the electrifying love story of Gena and Quadir to the small screen. When Gena, a sharp and independent young woman, falls for Quadir, a charming and calculated kingpin, their passion ignites a dangerous game. Determined to leave the streets behind for love, Quadir soon learns that in the world of power and betrayal, walking away comes at a deadly price.

Written by Cas Sigers-Beedles, episodes will be directed by Salvatore Sclafani, Preston A. Whitmore II, Vivica A Fox, Jamal Hill, David Wolfgang and D’Angela Steed. Manny Halley is an executive producer and producing via his A Manny Halley Productions banner. Production of the series will commence this fall in Los Angeles.

Said Halley, “Extending the True to the Game franchise via episodic storytelling allows us to really go deep into the world and characters created by Terri Woods and enjoyed by millions around the world. These are charismatic and complex characters that audiences really want to spend time with and explore in authentic ways. We have a collective vision for how this series plays out that services the appetite for lovers of the franchise as well as those who will be discovering the story for the first time.”

True to the Game franchise started in 2017 with Columbus Short, Vivica A. Fox, Erica Peeples, Jeremy Meeks, Andra Fuller and Malcolm David Kelley starring in the first installment directed by Preston A Whitmore II. Two more films True to the Game 2 and 3 were released in 2020 and 2021, respectively and garnered a cult following on streaming and cable. All films were produced by Halley’s Imani Media Group and distributed under Faith Media Distribution including limited theatrical releases.

Sierra Capri is represented by Independent Artists Group (IAG) and Aligned Entertainment. Bentley Green is represented by Independent Artists Group (IAG) and LBI Entertainment. Vivica A. Fox is represented by Sheila Legette Entertainment and A3 Artists Agency. Angell Cornwell is represented by Priluck Company and Yorn, Levine, Barnes, Krintzman, Rubenstein, Kohner, Endlich, Goodell & Gellman.

Halley most recently completed production in Los Angeles on Lot Patrol, a comedy TV series he created with Ernest Dancy starring DeRay Davis, Carl Anthony Payne II, Tamera Kissen, Darius McCrary and comedians Skeet Carter, TK Kirkland, Alex Thomas and Tanjareen Thomas.

Manny Halley is an accomplished film and television producer, talent manager, and entertainment executive who founded and runs the multidimensional Imani Media Group, which made a name for itself in the music industry for more than two decades, working with recording artists including Nicki Minaj, Young Thug, and Keyshia Cole.

Halley has produced and distributed multiple films and television projects, collaborating with the likes of Netflix, Tubi, BET, Apple TV, and Amazon Prime Video. Imani MG’s film and TV distribution arm, Faith Media Distribution, has worked with AMC Theatres, Netflix, BET, and Sony Home Entertainment, distributing films such as True to the Game and its sequels. In television, he’s made scripted drama series Legacy and the crime drama Angel for BET as well as the reality series Keyshia Cole: The Way It Is, and the spinoff, Frankie and Neffe.